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ABSTRAK
Penyebab utama hipertiroidisme adalah Penyakit Grave (GD). Ia merupakan 
penyakit autoimun dimana berlaku pengikatan antibodi terhadap reseptor hormon 
perangsang tiroid (TRAb). Tujuan kajian ini adalah untuk memvalidasi pengujian 
TRAb dari segi kejituan, sensitiviti, spesifisiti dan nilai cut-off. Ujian kejituan (CV) 
dilakukan secara dalam masa dan sela masa menggunakan dua tahap kawalan 
kualiti pada julat kepekatan  rendah 3.78-7.02 IU/L dan julat kepekatan tinggi 
13.5-21.2 IU/L. Untuk menentukan sensitiviti, spesifisiti dan nilai cut-off, 124 
sampel serum  dari 46 GD , tujuh tiroiditis Hashimoto (HD), 11 goiter nodular 
non-autoimmune (NAG), dua kanser tiroid and 58 normal sebagai kawalan telah 
diambil secara retrospektif. Kejituan  dalam masa adalah 2.4% pada kepekatan 
3.90 IU/L(julat: 3.78-7.02 IU/l) and 0.8% pada kepekatan 20.80 IU/L (julat:13.5-21.2 
IU/l). Kejituan keseluruhan adalah  3.8% pada kepekatan 3.80 IU/L (julat:13.5-21.2 
IU/l)  dan 1.0% pada 20.8 IU/L (julat:13.5-21.2 IU/l).  Analisa Receiver-operating 
characteristic (ROC) menunjukkan sensitiviti terbaik (94%) dan spesifisiti terbaik 
(98%) adalah pada nilai cut-off 1.69 IU/L. Positive predictive value (PPV) dan 
negative predictive value (NPV) berada pada  95% dan 94%.  Pada nilai 1.69 IU/l 
ini, didapati sensitiviti untuk 29 sampel pesakit yang baru didiagnosa dengan GD 
berada pada 94%. Dari kajian ini didapati esai TRAb yang mengambil masa 27 
minit ini mempunyai kejituan yang baik, sensitiviti yang tinggi untuk mengesan 
penyakit GD dan spesifisiti yang bagus untuk membezakan GD dari penyakit tiroid 
yang lain dan membantu dalam rawatan pesakit tiroid. 
Kata kunci: penyakit Graves, reseptor hormon perangsang thyroid, kejituan, sensitiviti, 
spesifisiti 
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ABSTRACT
The most common cause of hyperthyroidism is Graves disease (GD) which is 
characterised by the presence of autoantibodies which binds to the TSH receptor 
(TRAb). Recently, a rapid, fully automated electrochemiluminescent immunoassay 
ElecsysAnti-TSHR for detection of autoantibodies to TSH receptor was made 
available for routine clinical use. The objective of this study is to evaluate this assay 
and to determine the sensitivity, specificity and cut-off value. Interassay and total 
imprecision (CV) were determined at 3.78-7.02 IU/L and 13.5-21.2 IU/L respectively. 
A total of 124 samples which comprised of 46 GD, seven Hashimoto thyroiditis (HD), 
11 non autoimmune nodular goitre (NAG), 2 thyroid cancers (Ca) and 58 normal 
controls were retrospectively analysed to determine the sensitivity, specificity and 
cut-off value. Inter-assay CV’s were 2.4% at a concentration of 3.90 IU/L (range: 
3.78-7.02 IU/l) and 0.8% at 20.80 IU/L (range:13.5-21.2 IU/l). Total imprecision was 
3.8% at a concentration of 3.80 IU/L (range:13.5-21.2 IU/l)  and 1.0% at 20.8 IU/L 
(range:13.5-21.2 IU/l).  The ROC analysis of patients with GD, other thyroid disorders 
and normal controls revealed that the highest sensitivity (94%) and specificity (98%) 
were seen at cut-off value of 1.69 IU/L. Positive predictive value (PPV) and negative 
predictive value (NPV) was 95% and 94% respectively. At this derived cut-off value 
of 1.69 IU/L, we found that the sensitivity of TRAb positivity within the group of 
29 newly diagnosed GD patients was 94%. Our results demonstrate that this fully 
automated assay with testing time of 27 minutes has high sensitivity in detecting 
GD and high specificity for discriminating other thyroid disease and represent major 
improvement in the diagnosis and management of patients with thyroid diseases.  
Key words: Graves disease, TSH Receptor, reproducibility, sensitivity, specificity 
INTRODUCTION
Graves disease (GD) is a thyroid-specific 
autoimmune disease characterised by 
the presence of autoantibodies which 
binds to the TSH receptor (TRAb) and 
leads to overactivity of the thyroid 
gland which clinically manifest as 
hyperthyroidism. Besides that, the 
inflammation of the eye muscles by 
attacking autoantibodies give rise to 
Graves orbitopathy (GO). 
 The detection of TRAb is valuable 
in confirming the diagnosis of GD 
in mild hyperthyrodism, euthyroid 
Graves ophtalmopathy without 
goiter, differentiating GD from other 
toxic nodular goiter or facticious 
thyrotoxicosis (Weetman et al. 2000) 
and recent studies have shown that 
TRAb detection is potentially useful in 
predicting outcome in patient with GD 
and GO respectively. (Smith et al. 2007) 
The measurement of TRAb has been 
shown to be valuable in determining 
the causes of post partum thyrotoxicosis 
either due to post-partum thyroiditis 
or Graves disease. Furthermore this 
marker is useful in predicting the 
likelihood of either foetal or neonatal 
thyrotoxicosis in women undergoing 
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treatment or those who had thyroid 
ablation (Saravanan & Dayan 2001).
 In tandem with advance in 
technology, great improvement has 
been achieved in TRAb detection 
methodologies. At present, the bioassay 
and competitive TSH inhibition binding 
assays have been established. (Sanders 
et al. 2002; Scott et al. 2005; Smith et al. 
2007).  Among them, the competitive 
assays are the only validated routine 
test for TRAb analysis. These assays 
are based on the ability of TRAb to 
inhibit TSH receptor (TSHR) binding of 
labelled bovine TSH because purified 
bovine TSH has higher affinity towards 
TSH receptor than human TSH and 
it is a more suitable ligand for 125I or 
biotin labelling (Morgenthaler 1999). 
An alternative to bovine TSH have 
been available, for example, labelled 
mouse thyroid-stimulating monoclonal 
antibodies with similar performance 
(Sanders et al. 2002). More recently, 
Smith et al. (2005) developed an 
enzyme-linked immunosorbent assay 
(ELISA) using a labelled human thyroid 
stimulating monoclonal autoantibody 
M22 (Smith et al. 2005). In this assay, 
TRAb are detected based on their 
ability to inhibit the binding of labelled 
human monoclonal thyroid stimulating 
antibody (M22) to porcine TSH-coated 
ELISA plates. 
 Three comparison studies have been 
published (Kamijo 2003; Kamijo 2007; 
Liu et al. 2008) and two studies have 
found that the M22-biotin based ELISA 
have excellent sensitivity and specificity 
(Kamijo 2003; Kamijo 2007) while the 
remaining study showed  relatively poor 
precision (CV>20) (Liu et al. 2008). 
 As with other manual assays, 
the drawback of this ELISA assay is 
on their sensitivity, specificity and 
reproducibility. Furthermore, the 
typically long incubation times and 
intense manpower needed to perform 
this assay, make it unpopular in busy 
service laboratories.   
 Recently, a rapid (27 minutes), fully 
automated electrochemiluminescent 
immunoassay ElecsysAnti-TSHR 
for detection of autoantibodies to 
TSH receptor was made available for 
routine clinical use. The methodology 
of this assay incorporated the used 
of solubalized porcine TSH receptor 
immunocomplexed with a biotynylated 
mouse monoclonal antibody to the 
porcine TSH receptor and M22 human 
monoclonal antibody as a ruthenium- 
labelled assay ligand.  
 The aim of this study was to evaluate 
the ElecsysAnti-TSHR assay system 
in terms of reproducibility, sensitivity, 
specificity and to determine the cut-off 
value of this assay and the feasibility 
of this assay to be offered as a routine 
laboratory test for UKM Medical Centre 
(UKMMC).
MATERIALS AND METHODS
The study was conducted in the 
Chemical Pathology Laboratory, 
Department of Diagnostic Laboratory 
Services, UKMMC. 
Sample collection
The samples were acquired from the 
Endocrinology and Chemical Pathology 
laboratories and the diagnosis of the 
patients were based on the patients’ 
record from the hospital or laboratory 
information system.
 Inclusion criteria: Samples from 
patients with thyroid disorders which 
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include GD, Hashimoto  thyroiditis 
(HD), non autoimmune nodular goitre 
(NAG), thyroid cancer (Ca).
Reproducibility study (Coefficient 
variation, CV): 
The intra-assay imprecision CV 
was determined by 21 replicates 
in a single run on Cobas e411 
electrochemiluminescent immunoassay 
analyzer using a manufacturer control 
material of two levels PreciControl 
Thyro 1 (PCThyro 1 range: 3.78-7.02 
IU/L ) and  and  PreciControl Thyro 2 
(PCThyro 2 range: 13.5-21.2 IU/L).
 Total imprecision CV study was 
performed according to CLSI/NCCLS 
guideline EP5 A2 using aliquots of 
control materials PC Thyro 1 (range: 
3.78-7.02 IU/L) and PC Thyro 2 (range: 
13.5-21.2 IU/L) which were analysed 
in two determinations per run and two 
runs per day for five days.
Sensitivity, specificity and cut-off 
value:
The determination of optimal decision 
threshold level for positivity by receiver-
operating characteristic (ROC) analysis 
was performed using serum from 
apparently healthy subjects, patients 
with GD and patients with other 
thyroid diseases which were acquired 
retrospectively. 
Duration of assay performance
To validate the claim by the 
manufacturer that the total duration of 
this assay is 27 minutes, we examined 
the time from the samples was loaded 
in the analyzer and the time the result 
was made available by the analyzer.
Test principle
The ElecsysAnti-TSHR assay is a third 
generation assay using a preformed 
immunocomplex based on native 
porcine TSHR solubalised from a 
thyroid cell membrane preparation 
and biotinylated anti-porcine TSHR 
mouse monoclonal capture antibody 
and a ruthenium labeled human TSHR 
stimulating monoclonal detection 
antibody (M22). The capture antibody 
binds to the C-terminal moiety of the 
porcine TSHR (Bolton et al. 1999) which 
does not interfere with the binding of 
TRAb or M22 to the TSHR. After addition 
of streptavidin-coated microparticles and 
ruthenium labeled M22, serum TRAb 
bound to the TSH receptor are detected 
by the ability to inhibit the binding 
of labeled M22. The entire complex 
becomes bound to the solid phase via 
interaction of biotin and streptovidin. 
Anti-TSHR is calibrated against the 
National Institute for Biological Standards 
and Control (NIBSC) 90/672 standard. 
The test measuring range was 0.3-40 
IU/l. The within run CV for PCThyro 
1 and PCThyro 2 were 3.1 and 1.4 
respectively and the total CV for PCThyro 
1 and PCThyro 2 were reported at 5.5 
and 2.4 respectively. The cut-off value 
was 1.75 IU/l. However, each laboratory 
should investigate the transferability of 
the expected values to its own patient 
population and if necessary determine 
its own reference range. 
Statistical analysis
All clinical and laboratory data were 
stored and analyzed using the Statistical 
Package for Social Science (SPSS) 
software version 17.0.
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 A receiver operator characteristic 
(ROC) curve was constructed to 
determine the sensitivity, specificity 
and cut-off value.
 In all statistical analyses, p < 0.05 
(95% confidence interval) were 
considered significant.
RESULTS
Reproducibility study (Coefficient 
variation CV): 
The mean value for PreciControl 
Thyro 1 and 2 were 3.90 IU/l (range: 
3.78-7.02 IU/l and 20.80 IU/l (range 
13.50-21.20 IU/L) respectively. The 
intra-assay CVs were 2.4% and 0.8% 
for level PreciControl Thyro 1 and 2 
respectively. The total imprecision were 
3.8% and 1.0% for PreciControl Thyro 
1 (mean: 3.8 IU/l, range: 3.78-7.02 
IU/l) and PreciControl Thyro 2 (mean: 
20.80 IU/l, range 13.50-21.20 IU/L). 
Results of the reproducibility study are 
summarized in Table 1.
Sensitivity, specificity and cut-off 
value:
A total of 124 samples which comprised 
of 46 GD (29 newly diagnosed GD 
and not on antithyroid therapy), 7 
HD, 11 NAG, 2 Ca and 58 normal 
controls were retrospectively analysed 
to determine the sensitivity, specificity 
and cut-off value. The patients’ general 
characteristics are shown in Table 2. 
The samples were divided into two 
cohorts; sensitivity cohort comprises 
of the GD patients and the specificity 
cohort are made up by 20 patients with 
other thyroid diseases and 58 normal 
control subjects.  The mean age of 
the study population was 40.3±16.1 
years (range: 14-69 years). There was 
significant difference between the age 
of the patients in the sensitivity cohort 
and those in the specificity cohort, 
(35.3±15.7 years vs 42.7±16.4 years, 
(p<0.05)). Female preponderance was 
seen in both sensitivity and specificity 
cohorts. The majority of the study 
population was Malay followed by 
Chinese and Indian in both cohorts. 
(Table 2) 
 The ROC analysis showed an area 
under curve (AUC) of 0.99 (95% Cl: 
0.98-1.0). The optimal pair of sensitivity 
(94%) and specificity (98%) was found 
at a TRAb level of 1.69 IU/l (Figure 2). 
Positive predictive value (PPV) and 
negative predictive value (NPV) was 
95% and 94% respectively
Duration of assay performance
The mean total duration of the assay 
was 25.70±0.02 minutes (n=124).  This 
finding validated the manufacturer’s 
claim of the total assay duration of 27 
minutes.
DISCUSSION
The diagnosis of Graves hyperthyroidism 
is based on the clinical presentation 
and biochemical changes of 
hyperthyroidism. Traditionally, serum 
TSH and free T4 are measured to confirm 
the diagnosis of hyperthyroidism. 
 The measurement of serum TRAb 
is not routinely done because the 
diagnosis of GD can nearly always be 
made correctly based on the clinical 
findings. Furthermore, the inability 
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Table 1: Reproducibility study (Coefficient variation, CV) 
Material Range( IU/l) Mean (IU/l) CV
Inter assay CV, n =21 replicates in a single run
PreciControl Thyro 1  3.78-7.02 3.90 2.4%
PreciControl Thyro 2  3.50-21.20 20.80 0.8%
Total CV, n = 40 replicates in 10 runs
PreciControl Thyro 1  3.78-7.02 3.80 3.8%
PreciControl Thyro 2  13.50-21.20 20.80 1.0%





(n = 46:29 newly diagnosed)
Specificity Cohort 
(Normal Control Non 
Graves Disease) 
(n = 78 )






Male 48 (38.7%)      17 (36.9%)  33 (42.3%)
Female  76 (61.3%)  29 (63.1%) 45 (57.7%)
Race 
Malay   72 (58.1%) 20 (43.5%) 37 (47.4%)
Chinese   46  (37.1%) 24  (52.2%) 35  (44.9%)
Indian         6 (4.8%)    2 (4.3%) 4 (5.1%)
Others 2 (2.6%)
Normal Control 58
Non Graves Disease 20
Graves Disease 46
of the routine laboratory to perform 
this test partly due to the facts that 
different methodology gives different 
sensitivity and specificity and the test 
method can be cumbersome. With 
great improvement in TRAb detection 
methodologies, this test can be done 
routinely in most laboratories.
 We   evaluated  the  third 
generation, fully automated 
electrochemiluminescent immunoassay 
ElecsysâAnti-TSHR for detection of 
autoantibodies to TSH receptor.
 From this study, the intra-assays and 
total imprecision CVs were found to 
be less than 5%. This finding showed 
that ElecsysâAnti-TSHR assay meets 
the requirement CVs of less than 20%. 
(Hermsen et al. 2009)
 With regards to the cut-off value, 
the optimal pair of sensitivity (94%) 
and specificity (98%) was found at 
TRAb level of 1.69 IU/L. The calculated 
Positive predictive value (PPV) and 
Negative predictive value (NPV) were 
96% and 97% respectively. We further 
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studied the 29 newly diagnosed GD 
patients; at the derived cut-off value of 
1.69IU/L, we found that the sensitivity 
of TRAb assay was 94%. 
 Our finding was different from the 
manufacturer expected value and other 
studies (Hermsen et al. 2009; Schott 
et al. 2009) which reported the cut-off 
value as 1.75 IU/l. When we used the 
calculated cut-off for TRAb positivity of 
1.75 IU/l, we found the sensitivity and 
specificity of 87% (95% CI: 0.86- 0.93) 
and 99% (95% CI: 0.97- 0.99). 
 This discrepancy in the cut-off value 
could be due to the difference in the 
studied population and small sample 
numbers. In this study we included the 
GD which already received antithyroid 
drug therapy including GD patient on 
long-term follow up, while in the study 
by Hermsen et al. (2009) only the 
untreated GD patients were included 
as sensitivity cohort.  We included 
this group of patient to simulate the 
requirements in clinical routine when 
patients are included with long-lasting 
history of GD and potential negative 
TRAbs. Schott et al. (2009),  performed 
two sets of ROC analysis, the first 
analysis include only the untreated GD 
patients as sensitivity cohort whilst the 
other include all the GD patients; they 
found that at 1.75IU/l, lower sensitivity 
and good specificity were found when 
all GD patients were analysed together; 
a finding which was similar to ours. 
 From this study, we concluded 
that the fully automated 
Figure 1: Illustration of the TSH receptor complex and the competitive test principle
Figure 2: The ROC curve performed on 46 
GD (sensitivity cohort), 20 patients with 
other thyroid disease and 58 apparently 
normal control (specificity cohort) The 
optimal cut of value was calculated at 
1.69 IU/l (sensitivity 94%, specificity 
98%), AUC 0.99 (95% CI: 0.98-1.0)
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electrochemiluminescent immunoassay 
ElecsysAnti-TSHR assay with testing 
time of 27 minutes has excellent 
reproducibility with high sensitivity in 
detecting GD and high specificity for 
discriminating other thyroid diseases. 
Moreover, with the rapid turn-around 
time and less man power needed than 
the manual assay, it is feasible to be 
offered as a routine laboratory test and 
represent a major improvement in the 
diagnosis and management of patients 
with thyroid diseases.  
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